During the 17th ICML, the Lymphoma Hub spoke with Georg Lenz, Münster University Hospital, Münster, DE. We asked for a summary of Pola-R-CHP (polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone) vs R-CHOEP (cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and etoposide) treatment in young patients with high-risk diffuse large B-cell lymphoma (DLBCL). Lenz highlights the efficacy and safety data of each treatment for this population of patients.
Visit www.lymphomahub.com for more information on this topic.